Advanced search
Publication Cover
Cancer Biology & Therapy Volume 19, 2018 - Issue 12
Submit an article Journal homepage
1,480
Views
13
CrossRef citations to date
0
Altmetric
Bedside to Bench Report

Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review

Min JinCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaView further author information
,
Jun CaiDepartment of Oncology, First Affiliated Hospital of Yangtz University, Jingzhou, ChinaView further author information
,
Xuan WangDepartment of Oncology, First Affiliated Hospital of Yangtz University, Jingzhou, ChinaView further author information
,
Tao ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCorrespondence[email protected]
View further author information
&
Yingchao ZhaoCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaCorrespondence[email protected]
View further author information
Pages 1088-1092 | Received 12 Jan 2018, Accepted 17 Jun 2018, Published online: 15 Aug 2018

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Yu-Jia Wang, Ling Tang, Xu-Hong Lu, Ji-Tao Liu, Yuan-Yuan Wang, Hong-Xia Geng, Xue-Tao Li & Quan An. (2023) Efficacy of epi-1 modified epirubicin and curcumin encapsulated liposomes targeting-EpCAM in the inhibition of epithelial ovarian cancer cells. Journal of Liposome Research 33:2, pages 197-213.
Read now
Meng Li, Junna Cai, Xiaorui Han & Yue Ren. (2020) Downregulation of circNRIP1 Suppresses the Paclitaxel Resistance of Ovarian Cancer via Regulating the miR-211-5p/HOXC8 Axis. Cancer Management and Research 12, pages 9159-9171.
Read now
Jindi Zhang, Anyang Li, Qi Jiang, Feiyun Zheng & Haiyan Zhu. (2019) Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study. Drug Design, Development and Therapy 13, pages 3913-3918.
Read now

Articles from other publishers (10)

Aikaterini Skorda, Marie Lund Bay, Sampsa Hautaniemi, Alexandra Lahtinen & Tuula Kallunki. (2022) Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises. Cancers 14:24, pages 6257.
Crossref
Baohong Jiang, Hongbo Zhu, Liting Tang, Ting Gao, Yu Zhou, Fuqiang Gong, Yeru Tan, Liming Xie, Xiaoping Wu & Yuehua Li. (2022) Apatinib Inhibits Stem Properties and Malignant Biological Behaviors of Breast Cancer Stem Cells by Blocking Wnt/β-catenin Signal Pathway through Downregulating LncRNA ROR. Anti-Cancer Agents in Medicinal Chemistry 22:9, pages 1723-1734.
Crossref
Chong Guo, Chaoying Song, Jiali Zhang, Yisong Gao, Yuying Qi, Zongyao Zhao & Chengfu Yuan. (2022) Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine. Genes & Diseases 9:3, pages 668-681.
Crossref
Shenglong Li. (2021) Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma. Frontiers in Oncology 11.
Crossref
Juemin Fang, Na Ding, Xianling Guo, Yan Sun, Zhiwei Zhang, Bailu Xie, Zhong Li, Hui Wang, Wei Mao, Zhicai Lin, Fei Qin, Min Yuan, Wenqi Chu, Huanlong Qin, Qijun Qian & Qing Xu. (2021) αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib. Journal for ImmunoTherapy of Cancer 9:2, pages e001162.
Crossref
Qiao Wang, Hongling Peng, Xiaorong Qi, Min Wu & Xia Zhao. (2020) Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduction and Targeted Therapy 5:1.
Crossref
Xiaodan Sun, Ji Li, Yizhuo Li, Shouhan Wang & Qingchang Li. (2020) Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells. Oxidative Medicine and Cellular Longevity 2020, pages 1-19.
Crossref
Feixue Xu, Xiaoqiang Si, Jingran Du, Feihua Xu, Aihong Yang, Caixia Zhang, Xiucai Zhang & Yongxiu Yang. (2019) Downregulating SynCAM and MPP6 expression is associated with ovarian cancer progression. Oncology Letters.
Crossref
. (2019) Epirubicin/rivoceranib. Reactions Weekly 1737:1, pages 125-125.
Crossref
Dongsheng Wang, Chenglong Zhao, Liangliang Gao, Yao Wang, Xin Gao, Liang Tang, Kun Zhang, Zhenxi Li, Jing Han & Jianru Xiao. (2018) NPNT promotes early-stage bone metastases in breast cancer by regulation of the osteogenic niche. Journal of Bone Oncology 13, pages 91-96.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.